Shravan Sivakumar

Dr. Shravan Sivakumar

University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Shravan SivakumarShravan Sivakumar
Shravan Sivakumar
Mehdi GhasemiMehdi Ghasemi
Mehdi Ghasemi
SSSteven C. Schachter
Steven C. Schachter
N-methyl-D-aspartate receptors (NMDARs) are widely distributed in the central nervous system (CNS) and play critical roles in neuronal excitability in the CNS. Both clinical and preclinical studies have revealed that the abnormal expression or function of these receptors can underlie the pathophysiology of seizure disorders and epilepsy. Accordingly, NMDAR modulators have been shown to exert anticonvulsive effects in various preclinical models of seizures, as well as in patients with epilepsy. In this review, we provide an update on the pathologic role of NMDARs in epilepsy and an overview of the NMDAR antagonists that have been evaluated as anticonvulsive agents in clinical studies, as well as in preclinical seizure models.

7 January 2022 in Neurocritical Care
Verified
Journal Article
Closed access
PDF file
Shravan SivakumarShravan Sivakumar
Shravan Sivakumar
STSpyridoula Tsetsou
Spyridoula Tsetsou
APAman B. Patel
Aman B. Patel
CSChristopher J. Stapleton
Christopher J. Stapleton
BGBenjamin L. Grannan
Benjamin L. Grannan
EREric S. Rosenthal
Eric S. Rosenthal


18 March 2022 in Radiology Case Reports
Verified
Journal Article
Open access
LCLauryn Currens
Lauryn Currens
Shravan SivakumarShravan Sivakumar
Shravan Sivakumar
AJAdalia H. Jun-O'COnnell
Adalia H. Jun-O'COnnell
CICarolina Ionete
Carolina Ionete
Mehdi GhasemiMehdi Ghasemi
Mehdi Ghasemi
Despite widespread screening and active management of syphilis infection, the rate of secondary and tertiary syphilis has increased over the past decade in the United States, especially with human immunodeficiency virus co-infection. We report a case of ischemic strokes in the middle cerebral artery (MCA) territory with focal stenosis of the left M1 segment of the MCA resulting from neurosyphilis with manifestation of subacute intermittent right-sided hemi-body numbness and transient word finding difficulties in a young adult with no prior known history of syphilis or significant cerebrovascular risk factors. A diagnostic cerebral angiogram was done which was initially concerning for possibility of reversible cerebral vasoconstriction syndrome (RCVS). The serum Treponema pallidum RPR testing resulted positive (1:32 titer) as well as subsequent reactive cerebrospinal fluid (CSF) VDRL test (ratio, 1:8). The patient was treated with intravenous ceftriaxone as well as verapamil and recovered without any residual deficits. To the best of our knowledge, this is the first reported evidence of possible RCVS in a case of neurosyphilis and related ischemic stroke. This case underscores the importance of evaluation for syphilis in young patients with fewer known vascular risk factors, who present with an ischemic stroke. Given the higher rates of stroke recurrence in neurosyphilis relative to few other stroke risk factors, early diagnosis, and treatment is furthermore essential to prevent disease progression.

12 June 2023 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
MGMaria A. Garcia-Dominguez
Maria A. Garcia-Dominguez
BSBahadar S Srichawla
Bahadar S Srichawla
PPPeter Pacut
Peter Pacut
JQJared Quast
Jared Quast
Shravan SivakumarShravan Sivakumar
Shravan Sivakumar
Mehdi GhasemiMehdi Ghasemi
Mehdi Ghasemi
Background: The coronavirus disease 2019 (COVID-19) pandemic has unveiled a wide array of clinical biomarkers, and neurological manifestations in affected patients, necessitating further exploration. Methods: This single-center retrospective study evaluated clinical and neurological sequelae, demographics, as well as laboratory markers, in hospitalized COVID-19 patients from January to September 2020. Results: Among 1248 inpatients (median age: 68 years; 651 women), 387 (31%) were admitted to the ICU. Central nervous system (CNS) manifestations were present in 521 (41.74%) patients, while peripheral nervous system manifestations were observed in 84 (6.73%). COVID-19-related mortality occurred in 314 (25.16%) cases. ICU-admitted patients were predominantly male (P<0.0001), older (age≥60; P=0.037) and had more comorbidities such as diabetes (P=0.001), hyperlipidemia (P=0.043), and coronary artery disease (P=0.015). ICU patients exhibited more CNS manifestations (P=0.001), including impaired consciousness (P<0.0001) and acute cerebrovascular disease (P=0.023). Biomarkers linked to admission to the ICU included elevated white blood cell count, ferritin, lactate dehydrogenase, creatine kinase, blood urea nitrogen, creatinine, and acute phase reactants (e.g. erythrocyte sedimentation rate and C-reactive protein). ICU patients demonstrated lower lymphocyte and platelet counts compared to non-ICU patients. Those with CNS involvement in the ICU often exhibited elevated blood urea nitrogen, creatinine, and creatine kinase levels. Higher mortality from COVID-19 was observed in ICU patients (P<0.0001). Conclusions: Multiple serum biomarkers, comorbidities, and neurological manifestations in COVID-19 patients have been consistently documented and may be linked to increased morbidity, ICU admission, and mortality. Recognizing and addressing these clinical and laboratory markers is essential for effective COVID-19 management.

1 July 2025 in Stroke
Verified
Journal Article
Closed access
SVStephanie Vu
Stephanie Vu
NMNoor Mahmoud
Noor Mahmoud
Shravan SivakumarShravan Sivakumar
Shravan Sivakumar
FYForough Yazdanian
Forough Yazdanian
MFMarc Fisher
Marc Fisher
Secondary stroke prevention encompasses many approaches, including antithrombotic therapy, risk factor management, and a healthy lifestyle. Recommendations are typically based on the results of randomized clinical trials that provide evidence of benefit. However, in some situations, clinicians extrapolate the results of clinical trials into everyday practice, or trials have not provided sufficient information to make treatment decisions. This review will discuss 4 scenarios: dual-antiplatelet therapy, the perils of combining antiplatelet and anticoagulation, indications for statin therapy, and therapeutic considerations for patients with paroxysmal atrial fibrillation.